Phase 2 COURAGE trial data, published in The Lancet, show trevogrumab preserved up to 70% of muscle loss caused by semaglutide in obesity patients.

Boehringer Ingelheim's glucagon/GLP-1 dual agonist met both co-primary endpoints in SYNCHRONIZE-2, with full results published simultaneously in the New England

Egle's IL-2 agonist EGL-003 was well tolerated across four dose cohorts and produced selective Treg expansion, supporting a Q4 2026 atopic dermatitis

Integer Holdings has received early HSR termination for its $5.7bn acquisition by KKR, with a stockholder vote scheduled for 21 October 2026.

Highlight Therapeutics' intralesional BO-112 met its primary visual and pathological response endpoint in 61% of basal cell carcinoma patients.

Atsena Therapeutics reported sustained structural and functional gains in seven of nine treated eyes, with a BLA filing now targeted for late 2028.

Connect Biopharma's IL-4Rα antibody rademikibart met its primary endpoint in a Phase 2 COPD trial, eliminating hospital return visits versus placebo.

AI-enabled digital pathology shows aglatimagene drove sustained lymphocyte-tumour engagement more than two years after treatment in a phase 3 prostate cancer trial.

Ceribell's 510(k)-cleared software adds three quantitative EEG tools to its point-of-care platform, covering patients from premature neonates to adult ICU

MiNK's iNKT platform joins an $87 million ARPA-H programme seeking to eliminate cold-chain dependence in allogeneic cell therapy distribution.

New EASD 2026 data show CagriSema modifies brain food-cue responses and reduces ectopic fat, with bone health maintained during weight loss.

Moleculin has closed enrolment of 89 subjects in Part A of its pivotal MIRACLE trial, targeting a comprehensive data readout in Q1 2027.